Authors

Belzutifan Plus Lenvatinib Raises New Sequencing Questions in Advanced RCC

Daniel Heng, MD, MPH, FRCPC, discusses data from LITESPARK-011, second-line RCC sequencing, and managing belzutifan-associated anemia and hypoxia.

Real-World Treatment Reveals Discrepancy Between Actual Care and Clinical Trial Recommendations in MCL

A study of treatment patterns in adult patients with mantle cell lymphoma revealed a discrepancy between actual patterns of care and recommendations based on clinical trials.

The Desire to Always Do More

Jaffer A. Ajani, MD, has an unyielding drive that has resulted in breakthroughs in a deadly, but often overlooked, disease.

Toxicity Management and Product Differences

Experts explain how MRD negativity, B-cell aplasia, and CAR T persistence help predict durable remission across ALL therapies and products.

Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients

Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.

This Is How To Treat Cancer With Teacher Cells and Tumor Pieces

Lab-grown dendritic cells dressed with a sample of a patient’s tumor might someday train the immune system to fight cancer, a study shows.

Creating the In-Person Experience on a Virtual Platform

The coronavirus disease 2019 crisis has changed all aspects of medical education but perhaps altered clinical education most dramatically.

Non-Pharmacologic Therapies for Pain Management in Patients With Cancer: Opportunities and Challenges

Janet Abrahm, MD, FACP, FAAHPM, reviews the standing of the role of integrative therapies in cancer care.

Charting the Course for Patients With High-Risk Colon Cancer: 3 Months Versus 6 Months

In 5 years, it is estimated that approximately 20% of patients with stage II disease and 35% with stage III disease will experience disease recurrence. These estimates highlight the need to pursue progress in adjuvant systemic therapy in order to decrease recurrence rates and improve survival.

Important Considerations for Biomarker Testing in NSCLC at Key Points in Treatment Journey

The biomarker testing landscape has evolved over the years, affecting how oncologists approach lung cancer.

CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability

Although the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.

Novel Treatment Combinations for B-ALL May Help Patients Safely Achieve Remission: With Colin Vale, MD

Dr Vale discusses data from a phase 2 trial evaluating blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

TIL Therapy Brings New Hope for Patients With Advanced Melanoma

Rashmi Khanal, MD , of Fox Chase Cancer Center discusses how TIL therapy can give patients with aggressive disease more hope for the future.

Survey Aims to Identify COVID-19–Related Health Care Challenges in Latin America

Outbreaks of coronavirus disease 2019 are on the rise in Latin America, with more than 4 million confirmed cases. In response to this health crisis, elective medical procedures, including cancer screening and care, as well as treatment for conditions beyond the virus, have been held.

Scientists Create Nanoparticle That Helps Fight Solid Tumors

Researchers from Wake Forest University School of Medicine have discovered a possible new approach in treating solid tumors through the creation of a novel nanoparticle.

Closing Remarks and Emerging Data Outlook

Chinmay Jani, MD, of the University of Miami Sylvester Comprehensive Cancer Center, closes the discussion with Rajwanth R. Veluswamy, MD, MSCR, of the Perlmutter Cancer Center at NYU Langone Health, by naming the emerging data he is watching most closely in KRAS-mutated non-small cell lung cancer (NSCLC).

Responding to Resistance in Lung Cancer

The Transvesical Approach to Radical Prostatectomy: A Paradigm Shift in Minimally Invasive Surgery

Mutahar Ahmed, MD, FACS, details the transvesical surgical approach for radical prostatectomy.

BASECAMP-1 Trial Aims to Identify Patients With Solid Tumors Who Are Eligible for A2B530

The observational BASECAMP-1 screening study has started to identify patients with advanced solid tumors harboring somatic human leukocyte antigen-A*02 loss of heterozygosity who would be eligible to receive the novel Tmod CAR T-cell therapy, A2B530, if their cancer relapses after standard of care treatment.

Student Loan Debt, Immigration Status Often Drive Career Decisions for Fellows

Investigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.

Window of Opportunity Trials Are Needed for Novel Tissue Biomarker Analysis in Head and Neck Cancers

Drug development is a difficult and ever-changing process, with new agents being developed by industry and academic partners.

Leveraging BTK Inhibitors in Chronic Lymphocytic Leukemia

The choice of BTK inhibitor regimen for patients with chronic lymphocytic leukemia must be tailored to the patient, taking into consideration their preferences and comorbidities, as well as potential treatment-related adverse effects.

Hackensack Meridian Health Expands Cancer Services with New Facility at JFK University Medical Center

Hackensack Meridian JFK University Medical Center has expanded its comprehensive cancer care services with the opening of a newly renovated, four-story facility at 80 James Street in Edison, NJ

Navigating the Increasing Complexity of Therapeutic Sequencing for Relapsed/Refractory Multiple Myeloma

The treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.

IU Cancer Researchers Refining Colorectal Cancer Classification, Identifying New Targets for Treatment Using Cutting-Edge, Single-Cell Technology

Analyzing nearly 500,000 single cells, researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are refining how to classify colorectal cancer and identify new targets to develop effective therapies.

Breaking Down the Data in Bladder Cancer With Drs Aggen, Grivas, and Shore

David H. Aggen, MD, PhD, Petros Grivas, MD, PhD, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in bladder cancer presented during the 2025 ESMO Congress.

From the Ground Up: Daniel G. Haller, MD, Gets Giants of Cancer Care Award in GI Cancer

Daniel G. Haller, MD, says he has relied on “cheerful serendipity” throughout his life and career.